The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen
Not yet recruitingOBSERVATIONAL
Enrollment
158
Participants
Timeline
Start Date
May 1, 2024
Primary Completion Date
October 31, 2024
Study Completion Date
December 31, 2024
Conditions
CMV Infection or Reactivation After Allogenic HSCT
All Listed Sponsors
lead
Siriraj Hospital
OTHER
NCT06362720 - The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen | Biotech Hunter | Biotech Hunter